The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

Henry Krum; John J V McMurray; William T Abraham; Kenneth Dickstein; Lars Køber; Akshay S Desai; Scott D Solomon; Yanntong Chiang; Claudio Gimpelewicz; Bernard Reimund; M Atif Ali; Georgia Tarnesby; Barry M Massie; ATMOSPHERE Committees and Investigators

doi:10.1002/ejhf.408

The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

Henry Krum, John J V McMurray, William T Abraham, Kenneth Dickstein, Lars Køber, Akshay S Desai, Scott D Solomon, Yanntong Chiang, Claudio Gimpelewicz, Bernard Reimund, M Atif Ali, Georgia Tarnesby, Barry M Massie, ATMOSPHERE Committees and Investigators

Department of Clinical Medicine

16 Citations (Scopus)

Abstract

AIMS AND METHODS: To: (i) describe the baseline characteristics of patients in ATMOSPHERE and the changes in the planned analysis of ATMOSPHERE resulting from the mandated discontinuation of study treatment in patients with diabetes; (ii) compare the baseline characteristics of patients in ATMOSPHERE with those in the Prospective comparison of Angiotensin Receptor neprilysin inhibitors with Angiotensin converting enzyme inhibitors to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF); and (iii) compare the characteristics of patients with and without diabetes at baseline in ATMOSPHERE.

RESULTS: A total of 7063 patients were randomized into ATMOSPHERE April 2009-April 2014 at 755 sites in 43 countries. Their average age was 63 years and 78% were men. ATMOSPHERE patients were generally similar to those in PARADIGM-HF although fewer had diabetes, renal dysfunction, and were treated with a mineralocorticoid receptor antagonist. In ATMOSPHERE, patients with diabetes differed in numerous ways from those without. Patients with diabetes were older and had worse heart failure status but a similar left ventricular ejection fraction (mean 28%); they had a higher body mass index and more co-morbidity, especially hypertension and coronary heart disease. Mean estimated glomerular filtration rate was slightly lower in those with diabetes compared with those without.

CONCLUSION: ATMOSPHERE will determine whether patients with HF and reduced ejection fraction (particularly those without diabetes) benefit from the addition of a direct renin inhibitor to standard background therapy, including an angiotensin-converting enzyme inhibitor, beta-blocker, and a mineralocorticoid receptor antagonist. ATMOSPHERE will also determine whether aliskiren alone is superior to, or at least non-inferior to, enalapril.

Original language	English
Journal	European Journal of Heart Failure
Volume	17
Issue number	10
Pages (from-to)	1075-83
Number of pages	9
ISSN	1388-9842
DOIs	https://doi.org/10.1002/ejhf.408
Publication status	Published - Oct 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ejhf.408

ejhf.408Final published version, 124 KB

Cite this

Krum, H., McMurray, J. J. V., Abraham, W. T., Dickstein, K., Køber, L., Desai, A. S., Solomon, S. D., Chiang, Y., Gimpelewicz, C., Reimund, B., Ali, M. A., Tarnesby, G., Massie, B. M., & ATMOSPHERE Committees and Investigators (2015). The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure, 17(10), 1075-83. https://doi.org/10.1002/ejhf.408

The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE) : revised statistical analysis plan and baseline characteristics. / Krum, Henry; McMurray, John J V; Abraham, William T et al.

In: European Journal of Heart Failure, Vol. 17, No. 10, 10.2015, p. 1075-83.

Research output: Contribution to journal › Journal article › Research › peer-review

Krum, H, McMurray, JJV, Abraham, WT, Dickstein, K, Køber, L, Desai, AS, Solomon, SD, Chiang, Y, Gimpelewicz, C, Reimund, B, Ali, MA, Tarnesby, G, Massie, BM & ATMOSPHERE Committees and Investigators 2015, 'The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics', European Journal of Heart Failure, vol. 17, no. 10, pp. 1075-83. https://doi.org/10.1002/ejhf.408

@article{d8f05d8ffad04643b76f45a448d7c3af,

title = "The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics",

abstract = "AIMS AND METHODS: To: (i) describe the baseline characteristics of patients in ATMOSPHERE and the changes in the planned analysis of ATMOSPHERE resulting from the mandated discontinuation of study treatment in patients with diabetes; (ii) compare the baseline characteristics of patients in ATMOSPHERE with those in the Prospective comparison of Angiotensin Receptor neprilysin inhibitors with Angiotensin converting enzyme inhibitors to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF); and (iii) compare the characteristics of patients with and without diabetes at baseline in ATMOSPHERE.RESULTS: A total of 7063 patients were randomized into ATMOSPHERE April 2009-April 2014 at 755 sites in 43 countries. Their average age was 63 years and 78% were men. ATMOSPHERE patients were generally similar to those in PARADIGM-HF although fewer had diabetes, renal dysfunction, and were treated with a mineralocorticoid receptor antagonist. In ATMOSPHERE, patients with diabetes differed in numerous ways from those without. Patients with diabetes were older and had worse heart failure status but a similar left ventricular ejection fraction (mean 28%); they had a higher body mass index and more co-morbidity, especially hypertension and coronary heart disease. Mean estimated glomerular filtration rate was slightly lower in those with diabetes compared with those without.CONCLUSION: ATMOSPHERE will determine whether patients with HF and reduced ejection fraction (particularly those without diabetes) benefit from the addition of a direct renin inhibitor to standard background therapy, including an angiotensin-converting enzyme inhibitor, beta-blocker, and a mineralocorticoid receptor antagonist. ATMOSPHERE will also determine whether aliskiren alone is superior to, or at least non-inferior to, enalapril.",

author = "Henry Krum and McMurray, {John J V} and Abraham, {William T} and Kenneth Dickstein and Lars K{\o}ber and Desai, {Akshay S} and Solomon, {Scott D} and Yanntong Chiang and Claudio Gimpelewicz and Bernard Reimund and Ali, {M Atif} and Georgia Tarnesby and Massie, {Barry M} and {ATMOSPHERE Committees and Investigators}",

note = "{\textcopyright} 2015 The Authors European Journal of Heart Failure {\textcopyright} 2015 European Society of Cardiology.",

year = "2015",

month = oct,

doi = "10.1002/ejhf.408",

language = "English",

volume = "17",

pages = "1075--83",

journal = "European Journal of Heart Failure, Supplement",

issn = "1567-4215",

publisher = "JohnWiley & Sons Ltd",

number = "10",

}

TY - JOUR

T1 - The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE)

T2 - revised statistical analysis plan and baseline characteristics

AU - Krum, Henry

AU - McMurray, John J V

AU - Abraham, William T

AU - Dickstein, Kenneth

AU - Køber, Lars

AU - Desai, Akshay S

AU - Solomon, Scott D

AU - Chiang, Yanntong

AU - Gimpelewicz, Claudio

AU - Reimund, Bernard

AU - Ali, M Atif

AU - Tarnesby, Georgia

AU - Massie, Barry M

AU - ATMOSPHERE Committees and Investigators

PY - 2015/10

Y1 - 2015/10

N2 - AIMS AND METHODS: To: (i) describe the baseline characteristics of patients in ATMOSPHERE and the changes in the planned analysis of ATMOSPHERE resulting from the mandated discontinuation of study treatment in patients with diabetes; (ii) compare the baseline characteristics of patients in ATMOSPHERE with those in the Prospective comparison of Angiotensin Receptor neprilysin inhibitors with Angiotensin converting enzyme inhibitors to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF); and (iii) compare the characteristics of patients with and without diabetes at baseline in ATMOSPHERE.RESULTS: A total of 7063 patients were randomized into ATMOSPHERE April 2009-April 2014 at 755 sites in 43 countries. Their average age was 63 years and 78% were men. ATMOSPHERE patients were generally similar to those in PARADIGM-HF although fewer had diabetes, renal dysfunction, and were treated with a mineralocorticoid receptor antagonist. In ATMOSPHERE, patients with diabetes differed in numerous ways from those without. Patients with diabetes were older and had worse heart failure status but a similar left ventricular ejection fraction (mean 28%); they had a higher body mass index and more co-morbidity, especially hypertension and coronary heart disease. Mean estimated glomerular filtration rate was slightly lower in those with diabetes compared with those without.CONCLUSION: ATMOSPHERE will determine whether patients with HF and reduced ejection fraction (particularly those without diabetes) benefit from the addition of a direct renin inhibitor to standard background therapy, including an angiotensin-converting enzyme inhibitor, beta-blocker, and a mineralocorticoid receptor antagonist. ATMOSPHERE will also determine whether aliskiren alone is superior to, or at least non-inferior to, enalapril.

AB - AIMS AND METHODS: To: (i) describe the baseline characteristics of patients in ATMOSPHERE and the changes in the planned analysis of ATMOSPHERE resulting from the mandated discontinuation of study treatment in patients with diabetes; (ii) compare the baseline characteristics of patients in ATMOSPHERE with those in the Prospective comparison of Angiotensin Receptor neprilysin inhibitors with Angiotensin converting enzyme inhibitors to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF); and (iii) compare the characteristics of patients with and without diabetes at baseline in ATMOSPHERE.RESULTS: A total of 7063 patients were randomized into ATMOSPHERE April 2009-April 2014 at 755 sites in 43 countries. Their average age was 63 years and 78% were men. ATMOSPHERE patients were generally similar to those in PARADIGM-HF although fewer had diabetes, renal dysfunction, and were treated with a mineralocorticoid receptor antagonist. In ATMOSPHERE, patients with diabetes differed in numerous ways from those without. Patients with diabetes were older and had worse heart failure status but a similar left ventricular ejection fraction (mean 28%); they had a higher body mass index and more co-morbidity, especially hypertension and coronary heart disease. Mean estimated glomerular filtration rate was slightly lower in those with diabetes compared with those without.CONCLUSION: ATMOSPHERE will determine whether patients with HF and reduced ejection fraction (particularly those without diabetes) benefit from the addition of a direct renin inhibitor to standard background therapy, including an angiotensin-converting enzyme inhibitor, beta-blocker, and a mineralocorticoid receptor antagonist. ATMOSPHERE will also determine whether aliskiren alone is superior to, or at least non-inferior to, enalapril.

U2 - 10.1002/ejhf.408

DO - 10.1002/ejhf.408

M3 - Journal article

C2 - 26511146

SN - 1567-4215

VL - 17

SP - 1075

EP - 1083

JO - European Journal of Heart Failure, Supplement

JF - European Journal of Heart Failure, Supplement

IS - 10

ER -

The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this